上海醫藥(02607.HK)2024年度純利增20.82%至45.53億元 擬10派2.9元
格隆匯3月27日丨上海醫藥(02607.HK)公佈年度業績,截至2024年12月31日止年度,公司實現營業收入2,752.51億元(幣種爲人民幣,下同),同比增長5.75%。其中:醫藥工業實現銷售收入237.31億元,同比下降9.62%;醫藥商業實現銷售收入2,515.20億元,同比增長7.47%。
報告期內,公司實現歸屬於上市公司股東的淨利潤45.53億元,同比上升20.82%。其中:工業板塊貢獻利潤21.93億元,同比增長3.95%;商業板塊貢獻利潤33.85億元,同比增長1.05%;主要參股企業貢獻利潤4.70億元,同比下降12.98%。歸屬於上市公司股東的扣除非經常性損益的淨利潤爲40.65億元,同比增長13.04%。
報告期內,公司研發投入28.18億元。其中:研發費用23.94億元,同比增長8.64%。
報告期內,公司全年經營性現金流淨流入58.27億元,同比增長11.39%,繼續保持高質量發展。
此外,公司擬向全體股東每10股派發現金紅利人民幣2.90元(含稅)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.